ArticleScientific reports2019
Defining Dysbiosis for a Cluster of Chronic Diseases.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
191 citing papers in PubMed, 6 syntheses or guidelines pooled it, 319 citations in OpenAlex.
- The Integrative Role of Berberine in Gut Microbiota Modulation and Cardiometabolic Outcomes: A Systematic Review of Randomised Clinical Trials.Nutrients · 2026Pooled it
- Gut Microbiota Alterations Associated With Colonization by Multidrug-Resistant Organisms in ICU Patients: First Systematic Review and Meta-Analysis.MicrobiologyOpen · 2026Pooled it
- Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies.Alimentary pharmacology & therapeutics · 2025Pooled it
- Clinical trials targeting the gut-microbiome to effect ocular health: a systematic review.Eye (London, England) · 2023Pooled it
- The respiratory microbiota alpha-diversity in chronic lung diseases: first systematic review and meta-analysis.Respiratory research · 2022Pooled it
- Gut Microbiome Composition in Obese and Non-Obese Persons: A Systematic Review and Meta-Analysis.Nutrients · 2021Pooled it
- Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trial.Nature medicine · 2026Trial
- Effect of Lacticaseibacillus casei LC2W Supplementation on Glucose Metabolism and Gut Microbiota in Subjects at High Risk of Metabolic Syndrome: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.Probiotics and antimicrobial proteins · 2025Trial
- The effects of AG1® supplementation on the gut microbiome of healthy adults: a randomized, double-blind, placebo-controlled clinical trial.Journal of the International Society of Sports Nutrition · 2024Trial
- A Randomized Controlled Trial of Dietary Rice Bran Intake on Microbiota Diversity, Enteric Dysfunction, and Fecal Secretory IgA in Malian and Nicaraguan Infants.The Journal of nutrition · 2022Trial
- Specific gut microbiome signatures and the associated pro-inflamatory functions are linked to pediatric allergy and acquisition of immune tolerance.Nature communications · 2021Trial
- Trial
- Article
- Comparative microbiome profiling of betel quid chewers and non-chewers to identify dysbiotic microbial signatures.Scientific reports · 2026Article
- The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies.Journal of advanced research · 2026Review
- Article
- Viability Preservation of Probiotic Bacteria Encapsulated in Pectin-Reinforced pH-Responsive Composite Alginate Hydrogel Matrix as the Synbiotic Delivery System.Probiotics and antimicrobial proteins · 2026Article
- The impact of gut microbiota on leukemia and prospects for novel therapies.Infectious medicine · 2026Review
- SCARF1 deficiency exacerbates gut inflammation and autoimmune pathology.Scientific reports · 2026Article
- A data-driven universal gut microbiome health assessment: a machine learning framework trained on large metagenomic data.Frontiers in microbiology · 2026Article
131 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of many chronic diseases has increased over the last decades. It has been postulated that dysbiosis driven by environmental factors such as antibiotic use is shifting the microbiome in ways that increase inflammation and the onset of chronic disease. Dysbiosis can be defined through the loss or gain of bacteria that either promote health or disease, respectively. Here we use multiple independent datasets to determine the nature of dysbiosis for a cluster of chronic diseases that includes urinary stone disease (USD), obesity, diabetes, cardiovascular disease, and kidney disease, which often exist as co-morbidities. For all disease states, individuals exhibited a statistically significant association with antibiotics in the last year compared to healthy counterparts. There was also a statistically significant association between antibiotic use and gut microbiota composition. Furthermore, each disease state was associated with a loss of microbial diversity in the gut. Three genera, Bacteroides, Prevotella, and Ruminococcus, were the most common dysbiotic taxa in terms of being enriched or depleted in disease populations and was driven in part by the diversity of operational taxonomic units (OTUs) within these genera. Results of the cross-sectional analysis suggest that antibiotic-driven loss of microbial diversity may increase the risk for chronic disease. However, longitudinal studies are needed to confirm the causative effect of diversity loss for chronic disease risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.